Adam D. Cohen, MD
Hematology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Penn Medicine Provider

About me

  • Director, Myeloma Immunotherapy
  • Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: University of Pennsylvania School of Medicine
  • Residency: University of Pennsylvania Health System
  • Fellowship: Memorial Sloan-Kettering Cancer Center

What my patients think about me

Average Rating

790 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

December 2025
very professional.
December 2025
he's great
November 2025
very knowledgeable
November 2025
excellent dr explained everything

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Cohen is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Yu KL, Ho M, Paruzzo L, Stella F, Patel H, Hasanali Z, Kapur S, Waxman AJ, Vogl DT, Stadtmauer EA, Fraietta JA, Ruella M, Cohen AD, Garfall AL, Susanibar-Adaniya S Outcomes of relapse after teclistamab therapy in multiple myeloma , Blood Cancer Journal, 15(1): 2025,193. doi: 10.1038/s41408-025-01408-4.


Musa H, Mielnik M, Trudel S, Weisel K, Mockus-Daehn T, Ferron-Brady G, Hong Q, Ma Y, Pater S, Suchindran S, Zhou X, Richardson PG, Cohen AD*, Lowther DE* No evidence of B-cell maturation antigen loss or systemic immune impairment following belantamab mafodotin treatment in multiple myeloma , Haematologica: 2025


Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM Long-Term (5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma , Journal of Clinical Oncology, 43(25): 2025,2766-71


Ho M, Paruzzo L, Minehart J, Voruganti T, Devi P, Vogl DT, Cohen AD, Garfall AL, Waxman AJ, Kapur S, Stadtmauer EA, Adaniya SS, Longworth S Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma , Haematologica, 110(6): 2025,1436-42


Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies , Nature Medicine, 31(4): 2025,1134-1144


Stalker M, Garfall A, Cohen AD, Vogl DT, Djulbegovic M, Susanibar-Adaniya S, Stadtmauer E, Megherea O, Waxman AJ Safety and efficacy of teclistamab in patients with relapsed or refractory AL amyloidosis: a retrospective case series , European Journal of Haematology, 114(3): 2025,443-447


Costa LJ, Banerjee R, Mian H, Weisel KC, Bal S, Derman BA, Htut MM, Nagarajan C, Rodriguez C, Richter J, Frigault MJ, Ye JC, van de Donk NWCJ, Voorhees PM, Puliafito B, Bahlis N, Popat R, Chng WJ, Ho PJ, Kaur G, Kapoor P, Du J, Schjesvold F, Berdeja J, Einsele H, Cohen AD, Mikhael J, Biru Y, Rajkumar SV, Lin Y, Martin TG, Chari A International Myeloma Working Group Immunotherapy Committee Recommendation on Sequencing Immunotherapy for Treatment of Multiple Myeloma , Leukemia, 39(3): 2025,543-554


Gaballa MR, Puglianini OC, Cohen A, Vogl D, Chung A, Ferreri CJ, Voorhees P, Hansen DK, Patel KK BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement , Blood Advances, 9(5): 2025,1171-1180


Elghawy O, Deshpande S, Sussman J, Garfall A, Cohen A, Kapur S, Susanibar-Adaniya S, Vogl D, Waxman A, Stadtmauer E Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (auto-HCT) for multiple myeloma , Bone Marrow Transplantation, 60(1): 2025,64-68


Hasanali ZS, Razzo B, Susanibar-Adaniya SP, Garfall AL, Stadtmauer EA, Cohen AD CAR T cells in the treatment of Multiple Myeloma , Hematology/Oncology Clinics, 38(2): 2024,383-406